HealthCare Biotech
Wuhan Kanglu Biotechnology Co., Ltd. is a high-tech enterprise located in the Wuhan Optics Valley Precision Medical Industry Base, focusing on precision medical diagnostic products for major diseases such as tumors and cardiovascular and cerebrovascular diseases. The company integrates R&D, production, sales, and testing services. It has developed internationally leading FastProbe® rapid fluorescence in situ hybridization (FISH) probe preparation technology, reducing hybridization time from 3 days to a few hours with higher sensitivity and specificity. Kanglu Bio also pioneered a microfluidic chip fully automated cell FISH platform, automatic fluorescence scanning system, and AI result interpretation system, enabling rapid, automated, high-throughput, and intelligent FISH testing for bone marrow, peripheral blood, and exfoliated cells. Their product portfolio includes FISH and PCR diagnostic kits and automated FISH equipment, with multiple NMPA Class III medical device registrations and CE certifications. Their products are used for early tumor screening, auxiliary diagnosis, drug guidance, and prognosis evaluation, supporting precision treatment. The company has a comprehensive domestic and international marketing system, with products in over 20 countries and regions, recognized as a leading international brand in rapid FISH probes. They also operate a third-party medical testing laboratory providing advanced, accurate, and convenient testing services nationwide, including cytopathology and molecular pathology for disease warning, early diagnosis, personalized treatment, efficacy monitoring, prognosis, and recurrence surveillance.
HealthCare Biotech
Wuhan Kanglu Biotechnology Co., Ltd. is a high-tech enterprise located in the Wuhan Optics Valley Precision Medical Industry Base, focusing on precision medical diagnostic products for major diseases such as tumors and cardiovascular and cerebrovascular diseases. The company integrates R&D, production, sales, and testing services. It has developed internationally leading FastProbe® rapid fluorescence in situ hybridization (FISH) probe preparation technology, reducing hybridization time from 3 days to a few hours with higher sensitivity and specificity. Kanglu Bio also pioneered a microfluidic chip fully automated cell FISH platform, automatic fluorescence scanning system, and AI result interpretation system, enabling rapid, automated, high-throughput, and intelligent FISH testing for bone marrow, peripheral blood, and exfoliated cells. Their product portfolio includes FISH and PCR diagnostic kits and automated FISH equipment, with multiple NMPA Class III medical device registrations and CE certifications. Their products are used for early tumor screening, auxiliary diagnosis, drug guidance, and prognosis evaluation, supporting precision treatment. The company has a comprehensive domestic and international marketing system, with products in over 20 countries and regions, recognized as a leading international brand in rapid FISH probes. They also operate a third-party medical testing laboratory providing advanced, accurate, and convenient testing services nationwide, including cytopathology and molecular pathology for disease warning, early diagnosis, personalized treatment, efficacy monitoring, prognosis, and recurrence surveillance.